Central sleep apnea after acute coronary syndrome and association with ticagrelor use
| Autor: | N. Renaud, S. Mouram, A. Ben Driss, Ph. Meurin, C. Defrance, Jean-Yves Tabet, Hélène Weber, L. Bonnevie, R. Dumaine |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Acute coronary syndrome medicine.medical_specialty Ticagrelor Central sleep apnea Cheyne–Stokes respiration Ventricular Function Left 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Sleep study Acute Coronary Syndrome Aged business.industry Sleep apnea Stroke Volume General Medicine Middle Aged medicine.disease Sleep Apnea Central respiratory tract diseases 030228 respiratory system Apnea–hypopnea index Cardiology Female medicine.symptom business Hypopnea 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Sleep medicine. 80 |
| ISSN: | 1878-5506 |
| Popis: | Study objectives By modifying the apneic threshold, the antiplatelet agent ticagrelor could promote central sleep apnea hypopnea syndrome (CSAHS). We aimed to assess the association between CSAHS and ticagrelor administration. Methods Patients were prospectively included within 1 year after acute coronary syndrome (ACS), if they had no heart failure (and left ventricular ejection fraction ≥ 45%) and no history of sleep apnea. After an overnight sleep study, patients were classified as “normal” with apnea hypopnea index (AHI) Results We included 121 consecutive patients (mean age 56.8 ± 10.8, 88% men, mean body mass index 28.3 ± 4.4 kg/m2, left ventricular ejection fraction 56 ± 5%, at a mean of 67 ± 60 days (median 40 days, interquartile range: 30–80 days) after ACS. In total, 49 (45.3%) patients had AHI ≥ 15 (27 [22.3%] CSAHS %, 22 [18.2%] OSAHS). For 80 patients receiving ticagrelor, 24 (30%) had CSAHS with AHI ≥ 15, and for 41 patients not taking ticagrelor, only 3 (7.3%) had CSAHS with AHI ≥ 15 (chi-square = 8, p = 0.004). On multivariable analysis only age and ticagrelor administration were associated with the occurrence of CSAHS, (p = 0.0007 and p = 0.0006). Conclusion CSA prevalence after ACS is high and seems promoted by ticagrelor administration. Results from monocentric study suggest a preliminary signal of safety. Clinical trials.gov id NCT03540459. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect